SEC Form 4 · accession 0001144204-17-014235
Marker Therapeutics, Inc. · MRKR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Glynn Wilson
Officer — Chief Executive Officer · Director
Period of report
Mar 9, 2017
Accepted (ET)
Mar 13, 2017 · 4:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001094038
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 9, 2017 | A | 12,761 | $0.00 | A | 85,567 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the portion of a discretionary bonus award for 2016 payable as a restricted, immediately vested, common stock under the Company's 2014 Omnibus Stock Ownership Plan. The issuance of 12,761 shares of restricted common stock was based on the closing price or our common stock of $4.31 per share, on the day immediately preceding the date the 2016 bonus award was approved.